Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.64 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | PYCR1 | P32322 | 8/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659509 | 0.86 | HRH3 (0.82) | HRH3TAAR1ALDH1A1TSHRNOS3 | |
| SCHEMBL15128047 | 0.84 | PYCR1 (0.67) | HRH3TAAR1ALDH1A1TSHRPYCR1 | |
| SCHEMBL18598042 | 0.80 | AOC3 (0.60) | HRH3TAAR1ALDH1A1TSHRPYCR1 | |
| SCHEMBL9151599 | 0.80 | LSS (0.68) | HRH3TAAR1ALDH1A1KDM4EHTT | |
| Hydrochloric Acid SCHEMBL9151252 | 0.78 | LSS (0.68) | HRH3TAAR1ALDH1A1KDM4EHTT | |
| SCHEMBL1241075 | 0.78 | KDM4E (0.69) | TAAR1ALDH1A1PYCR1MAOBKDM4E | |
| SCHEMBL12679031 | 0.78 | HRH3 (1.00) | HRH3TAAR1ALDH1A1TSHRPYCR1 | |
| SCHEMBL10814136 | 0.77 | PYCR1 (0.63) | TAAR1ALDH1A1TSHRPYCR1MAOB | |
| SCHEMBL10050868 | 0.76 | HRH3 (0.67) | HRH3TAAR1ALDH1A1TSHRKDM4E | |
| SCHEMBL12374 | 0.76 | HRH3 (0.67) | HRH3TAAR1ALDH1A1TSHRPYCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667054-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | SHOUYAO HOLDINGS BEIJING CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-3880660-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| CN-113166065-B | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2025-04-15 | — | — | CN | disclosed |
| EP-4501912-A1 | NOVEL HETEROCYCLIC COMPOUND | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2025-02-05 | — | — | EP | disclosed |
| EP-3802492-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2024-11-06 | — | — | EP | disclosed |
| CN-118475560-A | Novel heterocyclic compound | 首药控股(北京)股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| US-11970469-B2 | Compounds useful in the treatment of disorders associated with mutant RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-04-30 | — | — | US | disclosed |
| CN-117417297-A | Novel heterocyclic compound | 首药控股(北京)股份有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-117255734-A | Polymer composition comprising polypropylene and hydrocarbon resin | 博里利斯股份公司 | 2023-12-19 | — | — | CN | disclosed |
| EP-0110434-B1 | STEROID INTERMEDIATES SUBSTITUTED AT POSITION 11, AND PROCESS FOR THEIR PREPARATION | ROUSSEL-UCLAF (FR) | 1986-10-29 | — | — | EP | disclosed |
| US-4519946-A | ANTIARTHRITIC, ANTIDIABETIC, ANTISECRETORY, AND HYPOTENSIVE AGENTS | ROUSSEL UCLAF (FR) | 1985-05-28 | — | — | US | disclosed |
| US-4496567-A | HSITAMINE H2 ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-01-29 | — | — | US | disclosed |
| EP-0110434-A1 | Steroid intermediates substituted at position 11, and process for their preparation | ROUSSEL-UCLAF (FR) | 1984-06-13 | — | — | EP | disclosed |
| US-4447424-A | ANTIFERTILITY, ANTIINFLAMMATORY AGENT, HORMONE INHIBITOR | ROUSSEL UCLAF (FR) | 1984-05-08 | — | — | US | disclosed |
| EP-0013071-B1 | PYRIMIDINONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1983-11-16 | — | — | EP | disclosed |
| US-4386085-A | ANTIGLUCOCORTICOIDS | ROUSSELL UCLAF (FR) | 1983-05-31 | — | — | US | disclosed |
| EP-0057115-A2 | Steroid derivatives substituted in the 11-beta position, process for their preparation, their utilization as medicaments and compositions containing them | ROUSSEL-UCLAF (FR) | 1982-08-04 | — | — | EP | disclosed |
| EP-0013071-A1 | Pyrimidinone derivatives, processes for preparing them and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-07-09 | — | — | EP | disclosed |
| WO-1980000966-A1 | NEW HISTAMINE H2-ANTAGONISTS | SMITH KLINE FRENCH LAB (GB) | 1980-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970469-B2 | Compounds useful in the treatment of disorders associated with mutant RAS | KRAS, NRAS, HRAS | HRH3 3017/4885TAAR1 4379/4885ALDH1A1 2940/4885 |
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | MAPT, MNAT1, MAT2A | HRH3 3998/4885TAAR1 796/4885ALDH1A1 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.